原发性硬化性胆管炎
失调
维管菌
发病机制
肠道菌群
微生物群
免疫系统
肝病
炎症性肠病
医学
免疫学
生物
病理
胃肠病学
疾病
细菌
生物信息学
链球菌
遗传学
作者
Mohammed Nabil Quraishi,Martin J. Sergeant,Gemma L. Kay,Tariq Iqbal,Jacqueline Chan,Chrystala Constantinidou,Palak Trivedi,James Ferguson,David H. Adams,Mark J. Pallen,Gideon M. Hirschfield
出处
期刊:Gut
[BMJ]
日期:2016-04-19
卷期号:66 (2): 386.1-388
被引量:160
标识
DOI:10.1136/gutjnl-2016-311915
摘要
Primary sclerosing cholangitis–IBD (PSC–IBD) is an inflammatory autoimmune hepato–biliary–enteric disease in which it is predicted that gut microbiota have potential pathophysiological effects, relevant to disease initiation and outcome. The recent article by Kummen et al 1 who reported that the gut microbiota in PSC is distinct compared with those from healthy controls and patients with UC without liver disease, is therefore of interest. However, it remains unclear if these alterations in the gut microbiota are a cause or an effect of liver disease, and there remains a challenging task to link dysbiosis with disease pathogenesis, as well as clarify whether faecal microbiota are entirely representative of communities of mucosa-associated bacteria, which might uniquely interact with immune and epithelial cells.
Nevertheless Kummen et al notably demonstrated that the Veillonella genus showed a marked increase in PSC–IBD, in comparison with both healthy controls and patients with UC alone. Given interest in the mechanism of lymphocyte tracking between the bowel and liver …
科研通智能强力驱动
Strongly Powered by AbleSci AI